CJC-1295 was developed by a Canadian company called "ConjuChem", who began trials during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, given that increased levels of exogenous HGH are resumed to increase liposysis (fat loss). However, the data captured indentified a whole lot of other health and performance benefiting properties that CJC-1295 posses. The benefits were comparable with the most potent BANNED anabolic drugs in regard to regeneration of body tissues including muscle, cartilage and bone, and it is just a Protein Peptide!
CJC-1295 stimulates the pituitary gland by binding to specific receptors to increase the production and secretion of endogenous GH. When administered inter muscularly, IGF-1 concentrations may increase allowing for an increased rate of tissue repair and an increase in muscle size. It may also boost strength, size, and stamina and has anti aging characteristics. In addition, CJC-1295 has anti- inflammatory properties, when administered into the injured tissue straight after its occurrence, it may stop swelling and pain and up regulate genetic pathways to signal repair of the injured tissue.
CJC-1295 does not interfere with your body's own GH release, that occurs around every 3 hours, but it amplifies it up to 10 times - this is equivalent to levels using synthetic HGH. Because CJC-1295 does not interfere with your growth cycle, you are not affected by any 'down' regulation, as found with synthetic GH that leads to undesired side effects. CJC1-295 is now detectable by specialised drug testing equipment.
The increase in the body's GH produced by the pituitary gland in response to CJC-1295 GHRH therapy has an anabolic effect on the tissues of the body and other benefits identified as follows:
*Note: If you are a registered professional athlete please consult the ASADA or WADA guidelines and your coach, club and/or sporting body before using this peptide.